Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.43 |
| ▸ | TUBB | P07437 | 2/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.43 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.43 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.43 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.43 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.43 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.43 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.43 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.43 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.43 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4330712 | 0.91 | MEN1 (0.44) | AKR1C3AKR1C2L3MBTL1MAPK1MEN1 | |
| SCHEMBL4324470 | 0.85 | L3MBTL1 (0.43) | AKR1C3AKR1C2L3MBTL1MAPK1MEN1 | |
| SCHEMBL15906148 | 0.85 | CCR2 (0.42) | CCR2MEN1KMT2ATUBB4ATUBB | |
| SCHEMBL8072182 | 0.82 | PDE4D (0.42) | CCR2MAPK1MEN1KMT2AMAPT | |
| SCHEMBL4530308 | 0.81 | AKR1C3 (0.45) | AKR1C3AKR1C2L3MBTL1MAPK1MEN1 | |
| SCHEMBL3807250 | 0.81 | MAPT (0.41) | AKR1C3AKR1C2L3MBTL1MAPK1MEN1 | |
| SCHEMBL3805746 | 0.80 | MAPK1 (0.45) | AKR1C3AKR1C2L3MBTL1MAPK1MEN1 | |
| SCHEMBL3796739 | 0.79 | AKR1C3 (0.55) | AKR1C3AKR1C2L3MBTL1MAPK1MEN1 | |
| SCHEMBL3803546 | 0.78 | HTT (0.53) | MAPK1MAPTALDH1A1 | |
| SCHEMBL3791606 | 0.78 | ALDH1A1 (0.45) | AKR1C3AKR1C2MAPK1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2014-10-09 | — | — | US | disclosed |
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2014-10-09 | — | — | US | disclosed |
| US-8791267-B2 | Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | DECODE GENETICS EHF (IS) | 2014-07-29 | — | — | US | disclosed |
| US-8791267-B2 | Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | DECODE GENETICS EHF (IS) | 2014-07-29 | — | — | US | disclosed |
| US-20120183522-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2012-07-19 | — | — | US | disclosed |
| US-20120183522-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2012-07-19 | — | — | US | disclosed |
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-12-31 | — | — | US | disclosed |
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-12-31 | — | — | US | disclosed |
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120183522-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4A, PDE4B, PDE3B | AKR1C3 559/4885AKR1C2 652/4885CCR2 198/4885 |
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4A, PDE4B, PDE3B | AKR1C3 559/4885AKR1C2 652/4885CCR2 198/4885 |
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4A, PDE4B, PDE3B | AKR1C3 559/4885AKR1C2 652/4885CCR2 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.